X0306 4 2022-05-05 0001082554 UNITED THERAPEUTICS Corp UTHR 0001231589 MAHON PAUL A C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING MD 20910 false true false false EVP & GENERAL COUNSEL Common Stock 2022-05-05 4 M 0 6000 111 A 42397 D Common Stock 2022-05-05 4 S 0 1300 189.3765 D 41097 D Common Stock 2022-05-05 4 S 0 3100 190.3573 D 37997 D Common Stock 2022-05-05 4 S 0 900 191.7233 D 37097 D Common Stock 2022-05-05 4 S 0 700 192.9221 D 36397 D Stock Options 111 2022-05-05 4 M 0 6000 0 D 2021-03-15 2028-03-15 Common Stock 6000 34552 D This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. This transaction was executed in multiple trades at prices ranging from $188.955 to $189.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $190.085 to $190.955. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $191.315 to $191.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $192.50 to $193.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021. /s/ John S. Hess, Jr. under Power of Attorney 2022-05-06